SCHEMBL21241836

SCHEMBL21241836

CCC(N)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.63
MAPT P10636 3/20 0.58
ELOVL1 Q9BW60 1/20 0.57
ROCK2 O75116 2/20 0.57
ROCK1 Q13464 2/20 0.57
ADORA3 P0DMS8 1/20 0.56
RAB9A P51151 2/20 0.56
NPC1 O15118 1/20 0.56
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
PARP1 P09874 1/20 0.56
MRE11 P49959 1/20 0.55
GSTO1 P78417 1/20 0.55
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 1/20 0.55
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22971724 1.00 HDAC6 (0.63) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL21224494 0.90 HDAC6 (0.67) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL21224492 0.90 HDAC6 (0.67) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL21241893 0.88 HDAC6 (0.64) HDAC6MAPTELOVL1ADORA3RAB9A
SCHEMBL21224358 0.88 HDAC6 (0.64) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL21241891 0.88 HDAC6 (0.64) HDAC6MAPTELOVL1ADORA3RAB9A
SCHEMBL21224359 0.88 HDAC6 (0.64) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL21224178 0.88 HDAC6 (0.70) HDAC6MAPTELOVL1ADORA3RAB9A
SCHEMBL21241786 0.88 HDAC6 (0.61) HDAC6MAPTELOVL1ROCK2ROCK1
SCHEMBL22971723 0.88 HDAC6 (0.61) HDAC6MAPTELOVL1ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC6 86/4885MAPT 2074/4885ELOVL1 2017/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC6 86/4885MAPT 2074/4885ELOVL1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.